Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Nanjing Legend Biotech Co., Ltd”

16 pharma patents match "Nanjing Legend Biotech Co., Ltd" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 16
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 16 pharmaceutical patents matching "Nanjing Legend Biotech Co., Ltd" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

16 results for “Nanjing Legend Biotech Co., Ltd” · 30,257 patents in full index Clear search

  1. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Nanjing Legend Biotech Co., Ltd · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  2. US 12168688

    Antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  3. US 11958903

    Single-domain antibodies against LAG-3 and uses thereof

    Nanjing Legend Biotech Co., Ltd · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  4. US 11932698

    Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

    Nanjing Legend Biotech Co., Ltd · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  5. US 11905327

    Single-domain antibodies and variants thereof against TIGIT

    Nanjing Legend Biotech Co., Ltd · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  6. US 11827713

    Chimeric antibody immune effector cell engagers and methods of use thereof

    Nanjing Legend Biotech Co., Ltd · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  7. US 11713353

    Single-domain antibodies and variants thereof against PD-1

    Nanjing Legend Biotech Co., Ltd · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  8. US 11708410

    Antibodies and variants thereof against TIGIT

    Nanjing Legend Biotech Co., Ltd · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  9. US 11673954

    Single-domain antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  10. US 11564945

    Chimeric antigen receptor and use thereof

    Nanjing Legend Biotech Co., Ltd · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  11. US 11505601

    Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum

    Nanjing Legend Biotech Co., Ltd · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  12. US 11472881

    Single-domain antibodies and variants thereof against CTLA-4

    Nanjing Legend Biotech Co., Ltd · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  13. US 11447573

    Multispecific antigen binding proteins and methods of use thereof

    Nanjing Legend Biotech Co., Ltd · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  14. US 11401317

    Human-CD123-targeting chimeric receptor ligand and application thereof

    Nanjing Legend Biotech Co., Ltd · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  15. US 11168146

    Compositions and methods for increasing protein half-life in a serum

    Nanjing Legend Biotech Co., Ltd · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  16. US 10407508

    Compositions and methods for increasing protein half-life in a serum

    Nanjing Legend Biotech Co., Ltd · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted